Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels.

And with that increasing complexity come rising costs and the risk of delays that can slow the delivery of critical medicines to patients awaiting treatments – and flatten drug sponsors’ return on ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

At Frontiers Health 2025, the conversation around global brand launches was evolving rapidly – and EVERSANA and its agency ...

The AI floodgates are open. The race belongs to those who can scale speed without losing traceability, and next year the AI ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use ...

Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...

Benger will take over from Roberts – who was named CEO in 2021 and announced her decision to step down in the summer – on ...